- Home
- BRY vs PYXS Comparison
BRY vs PYXS Comparison
Compare BRY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRY | PYXS |
|---|---|---|
| Founded | 1909 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.1M | 243.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRY | PYXS |
|---|---|---|
| Price | $3.48 | $4.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 577.5K | ★ 642.3K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $730,290,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $0.83 |
| 52 Week High | $5.09 | $5.55 |
Technical Indicators
Market Signals| Indicator | BRY | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 50.45 |
| Support Level | $3.32 | $4.10 |
| Resistance Level | $3.43 | $4.35 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 88.89 | 35.11 |
Price Performance
Historical ComparisonAbout BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.